Immunotherapy-Chemo combo takes on advanced sarcoma
NCT ID NCT04577014
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding an experimental immunotherapy drug called retifanlimab to standard chemotherapy (gemcitabine and docetaxel) is safe and effective for people with advanced soft tissue sarcoma that cannot be removed by surgery. About 98 participants will receive the combination. The main goal is to see how many patients are still alive without their cancer getting worse after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
retifanlimab (immunotherapy) plus gemcitabine and docetaxel (chemotherapy)
What this could lead to
If it works, this combination could offer a new treatment option that helps control advanced soft tissue sarcoma for longer than chemotherapy alone.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants. The immunotherapy may not improve outcomes and could cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••